The journal Immunotherapy, published by Future Science Group (FSG), has announced the release of a Special Focus Issue taking lessons from multiple areas of immunotherapy to highlight therapeutic solutions for COVID-19.
Immunotherapy was delighted to welcome Melissa Bersanelli from the University of Parma (Italy) as the Guest Editor for the Special Focus Issue.
“The heartfelt research of therapeutic solutions for COVID-19 remains a mission of doctors of all branches, sometimes contributing to creating new professional figures between immunology, infectious diseases and other specialties. Because union is strength” stated Bersanelli.
Highlights from the issue include a Case Report describing the efficacy of the anti-IL-6 antibody, tocilizumab, against the SARS-CoV-2 infection, and a Preliminary Communication looking at oncology patients who develop COVID-19 during treatment with immune checkpoint inhibitors.
Ebony Torrington, Commissioning Editor for Immunotherapy, added: “I am delighted with the response already received from experts in the field regarding the release of this Special Focus Issue. It has been a pleasure to work with all of the authors involved in the creation of this issue to produce insightful articles that we hope will benefit the field and lead to better understanding of treatment and care in the COVID-19 pandemic”
The issue is available online here: www.futuremedicine.com/toc/imt/12/15
Bersanelli’s foreword as the Guest Editor is free to read here: www.futuremedicine.com/doi/10.2217/imt-2020-0205
Immunotherapy is a MEDLINE-indexed, peer-reviewed journal from the Future Science Group covering information on key areas in this exciting field, including immuno-oncology, novel biotherapeutics, biosimilars and allergen immunotherapy. All forms of research are considered, from basic and translational science to health economics and outcomes research, real-world evidence and effectiveness studies. A wide range of invited and unsolicited articles are considered, including original research, narrative and systematic reviews, clinical trial protocols, consensus findings and network meta-analyses, written by thought leaders in the field from all areas of research and clinical practice. The journal offers rapid and open access publishing options.
About Future Science Group
Founded in 2001, Future Science Group is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. Future Science Group’s portfolio consists of three publishing imprints, Future Science, Future Medicine, Newlands Press, as well as a content development imprint, PharmaPlatforms. In addition to a core business of subscription and open access journal publishing, Future Science Group develops specialist knowledge networks and content hubs, enabling professionals to easily connect and collaborate with their peers in niche scientific fields.
The aim of Future Science Group is to serve the advancement of clinical practice and drug research by enhancing the efficiency of communication among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. www.future-science-group.com